[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Generate Biomedicines Inc (GENB)

Generate Biomedicines Inc (GENB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

When chip giant Nvidia (NVDA) shows interest in any company, analysts and investors take note. According to Nvidia’s most recent 13F filing, the company now owns 833,325 shares of AI biotech company Generate Biomedicines (GENB), with the position valued at around $10.4 million.

This investment might be small for Nvidia with its massive balance sheet and multi-billion-dollar AI infrastructure bets. However, for a small clinical-stage biotech company, Nvidia’s trust and investment could carry a lot of significance. GENB stock went public in late February 2026 and has already earned a “Strong Buy” consensus rating on Wall Street, despite rising just 8%...

Fundamentals

See More
  • Market Capitalization, $K 1,592,145
  • Shares Outstanding, K 128,192
  • Annual Sales, $ 31,893 K
  • Annual Income, $ -203,154 K
  • EBIT $ 0 M
  • EBITDA $ 0 M
  • 60-Month Beta N/A
  • Price/Sales 52.55
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings $-1.07 on 05/07/26
  • Next Earnings Date 08/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 3
  • High Estimate $-0.46
  • Low Estimate $-0.51
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.84 +9.97%
on 04/21/26
16.75 -22.26%
on 05/13/26
+0.90 (+7.43%)
since 04/20/26

Most Recent Stories

More News
This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

NVDA : 223.47 (+1.30%)
GENB : 13.02 (+4.83%)
NVS : 150.45 (+0.01%)
AMGN : 331.57 (+0.25%)
A Deep Dive Into NVIDIA’s Latest Portfolio Moves

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

NVDA : 223.47 (+1.30%)
CRWV : 101.28 (+1.47%)
GENB : 13.02 (+4.83%)
INTC : 118.96 (+7.36%)
SNPS : 498.93 (+1.02%)
COHR : 358.50 (+1.38%)
NBIS : 191.82 (-2.99%)
RXRX : 2.96 (+3.86%)
NOK : 13.62 (-0.37%)
LITE : 868.07 (-2.47%)
MRVL : 186.80 (+5.97%)
Generate Biomedicines: Q1 Earnings Snapshot

Generate Biomedicines: Q1 Earnings Snapshot

GENB : 13.02 (+4.83%)
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

SOMERVILLE, Mass. , May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ: GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026, and highlighted...

GENB : 13.02 (+4.83%)
Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering

SOMERVILLE, Mass. , Feb. 26, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) ("Generate"), a clinical-stage generative biology company pioneering the AI revolution in biotechnology...

GENB : 13.02 (+4.83%)

Key Turning Points

3rd Resistance Point 14.84
2nd Resistance Point 14.15
1st Resistance Point 13.58
Last Price 13.02
1st Support Level 12.33
2nd Support Level 11.64
3rd Support Level 11.07

See More

52-Week High 16.75
Fibonacci 61.8% 14.55
Fibonacci 50% 13.87
Fibonacci 38.2% 13.20
Last Price 13.02
52-Week Low 11.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.